REGAL Trial Anticipation: Social media buzz has intensified around SELLAS Life Sciences as the pivotal REGAL Phase 3 trial for GPS in AML nears its final analysis. Observers point to recent price swings driven by unconfirmed reports and spillover from broader biotech momentum.
Valuation and Risk Debate: Participants frequently note the pre-revenue biotech's elevated market capitalization amid ongoing cash position updates. Some highlight dilution concerns and limited market opportunity even if the binary readout succeeds, while others reference strong short interest and technical setups.
Catalyst Positioning: Discussions also cover upcoming SLS009 data in Q4 and overall sentiment toward the stock's volatility. Traders emphasize the high-stakes nature of the event without clear confirmation on event counts.
Note: This discussion summary was generated from an AI condensation of post data.
SELLAS Life Sciences Group Hedge Fund Activity
We have seen 132 institutional investors add shares of SELLAS Life Sciences Group stock to their portfolio, and 61 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- STATE STREET CORP added 4,600,202 shares (+54.8%) to their portfolio in Q2 2026, for an estimated $67,898,981
- ANSON FUNDS MANAGEMENT LP added 4,500,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $66,420,000
- BLACKROCK, INC. added 2,871,892 shares (+23.5%) to their portfolio in Q2 2026, for an estimated $42,389,125
- MARSHALL WACE, LLP removed 2,037,162 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $30,068,511
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 1,653,541 shares (+416.5%) to their portfolio in Q2 2026, for an estimated $24,406,265
- BNP PARIBAS FINANCIAL MARKETS added 1,025,006 shares (+2180.1%) to their portfolio in Q2 2026, for an estimated $15,129,088
- GEODE CAPITAL MANAGEMENT, LLC added 971,569 shares (+24.8%) to their portfolio in Q2 2026, for an estimated $14,340,358
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
